Oral Therapy, Microbiological Findings, and Comorbidity Influence the Outcome of Prosthetic Joint Infections Undergoing 2-Stage Exchange
Overview
Authors
Affiliations
Background: The aim of the present study was to investigate potential predictive factors of an unfavorable outcome in patients with prosthetic joint infection (PJI) undergoing 2-stage exchange.
Methods: Patients with PJI undergoing 2-stage exchange and observed over a 5-year period (2009-2013) were included. Cure was defined by the disappearance of infection after a 96-week follow-up period. Statistical analysis was performed using the Mann-Whitney U test, the Fisher exact test, and the multivariate analysis.
Results: One-hundred twenty-two patients with PJI were included (median age, 69 years [range, 36-80 years]; 48% males, 47 hip PJI, and 75 knee PJI). Known comorbidities related to an increased risk of infection were reported in 43 patients (35%). Microbiological definition was obtained in 101 (83%) patients, and Staphylococcus aureus was isolated in 44 (36%) patients. Coagulase-negative staphylococci were isolated in 41 (34%) patients. A favorable outcome was obtained in 102 of 122 patients (84%). After univariate analysis, bacterial growth from operative specimens (P = .007), growth of Gram-positive bacteria (P < .001), use of oral therapy (P = .01), and absence of known comorbidities (P = .02) were associated with favorable outcome. Administration of rifampin (P = .99) and results of blood analysis were not predictive of outcome. After multivariate analysis was applied, infection sustained by Gram-positive bacteria, administration of oral antibiotics, and absence of known comorbidities frequently resulted in favorable outcome.
Conclusion: A favorable outcome in patients with PJI undergoing 2-stage procedure was associated with an infection sustained by Gram-positive bacteria, absence of known comorbidities, and administration of oral therapy. Therefore, failure rate can be reduced with appropriate treatment choices.
Prats-Peinado L, Fernandez-Fernandez T, Marquez-Gomez M, Matas-Diaz J, Sanchez-Somolinos M, de la Villa-Martinez S Antibiotics (Basel). 2024; 13(6).
PMID: 38927204 PMC: 11200406. DOI: 10.3390/antibiotics13060538.
Oliveira B, Costa V, Gama I, Beskow M, Santos E Rev Bras Ortop (Sao Paulo). 2024; 59(1):e21-e28.
PMID: 38524719 PMC: 10957261. DOI: 10.1055/s-0043-1776019.
prosthetic joint-infection outcomes: Prospective, observational study on 43 patients.
Prie H, Meyssonnier V, Kerroumi Y, Heym B, Lidove O, Marmor S Front Med (Lausanne). 2022; 9:1039596.
PMID: 36569155 PMC: 9774483. DOI: 10.3389/fmed.2022.1039596.
Ryan S, Warne C, Osmon D, Tande A, Ledford C, Hyun M J Arthroplasty. 2022; 38(5):909-913.
PMID: 36496045 PMC: 10430476. DOI: 10.1016/j.arth.2022.12.006.
Bouji N, Wen S, Dietz M J Bone Jt Infect. 2022; 7(5):191-202.
PMID: 36267262 PMC: 9562697. DOI: 10.5194/jbji-7-191-2022.